Evidence map›Paper›PMID 28152432›Full record

Observational studyJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2017

Rates and determinants of incidence and clearance of cervical HPV genotypes among HIV-seropositive women in Pune, India.

Arati Mane, Vikrant V Sahasrabuddhe, Amit Nirmalkar, Arun R Risbud, Seema Sahay, Ramesh A Bhosale, Sten H Vermund, Sanjay M Mehendale

Abstract readObservational Study
In one paragraph

Observational study in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arati ManeNational AIDS Research Institute, Pune, India.
Vikrant V SahasrabuddheNational Cancer Institute, Rockville, USA. Electronic address: vikrant.sahasrabuddhe@nih.gov.
Amit NirmalkarNational AIDS Research Institute, Pune, India.
Arun R RisbudNational AIDS Research Institute, Pune, India.
Seema SahayNational AIDS Research Institute, Pune, India.
Ramesh A BhosaleByramjee Jeejeebhoy Government Medical College, Pune, India.
Sten H VermundVanderbilt University School of Medicine, Nashville, USA.
Sanjay M MehendaleNational Institute of Epidemiology, Chennai, India.

Funding

Vanderbilt University-CIDRZ AIDS International Training and Research ProgramD43TW001035 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 1998 to 2014
$10.9M
Cervical Cancer Screening in HIV-infected women in IndiaR21CA113465 · NCI · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2005 to 2006
$360k
FIC NIH HHS D43 TW001035Intramural NIH HHS Z99 CA999999NCI NIH HHS R21 CA113465
6 · The paper itself

Abstract

backgroundSeveral studies in recent years have documented the genotype-specific prevalence of HPV infection and wide diversity and multiplicity of HPV genotypes among HIV-seropositive women. Yet, information on changes in HPV genotype-specific incidence and clearance rates over time, and their correlation with clinical or immunologic factors among HIV-seropositive women is scarce.

objectivesWe conducted a prospective study to investigate the incidence and clearance rates of cervical HPV genotypes among HIV-seropositive women in India and expand the evidence base in this area of research. STUDY

designCervical samples were collected from n=215 HIV-seropositive women in Pune, India who underwent two screening visits separated by a median of 11-months (interquartile range: 8-18 months). HPV genotypes were determined by Roche Linear Array HPV assay. Individual genotype-specific and carcinogenicity-grouping-specific HPV incidence and clearance rates were calculated and the associations between incidence/clearance and age and HIV-related metrics were explored.

resultsIncidence and clearance rates for 'any HPV' and 'carcinogenic HPV' genotypes were 11.1 and 18.3, and 6.7 and 33.8, per 100 person-years, respectively. Incidence and clearance rates for HPV genotypes of alpha-9 species (HPV16, HPV31, HPV33, HPV35, HPV52 and HPV58) and alpha-7 species (HPV18, HPV39, HPV45, HPV59 and HPV68) were 5.8 and 2.04, and 32.1 and 53.5, per 100 person-years, respectively. Clearance of any HPV type was associated with increasing age of participants (odds ratio: 1.08, 95%CI: 1.004-1.17), although the association marginally lost its statistical significance when adjusted for CD4 counts and antiretroviral therapy status.

conclusionsGenotype-specific clearance rates of HPV were higher than corresponding incidence rates. The suggestion of a positive associations of increasing age with HPV clearance points to the need for etiologic studies on age-related hormonal changes on clearance of cervical HPV infection.

Indexed as

GenotypeAdultCervix UteriFemaleHIV InfectionsHumansIncidenceIndiaPapillomaviridaePapillomavirus InfectionsProspective StudiesClearanceGenotypesHIVHPVIncidenceNatural history

Identifiers

PMID28152432
PMCPMC5441893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.